期刊文献+

高血压病患者血清脂联素水平与左心室几何构型的关系 被引量:4

Relationship between serum adiponeetin and left ventrieular geometry in patients with essential hypertension
暂未订购
导出
摘要 目的探讨高血压病患者左心室重构的不同阶段血清脂联素(APN)水平与左心室儿何构型的关系.方法对133例高血压病患者进行超声心动图检查,依据左心室质量指数、左心窒相对室壁厚度将患者分为左心室正常构型组、左心室向心性重构组、左心室向心性肥厚组和左心室离心性肥厚组。30例健康体检者为对照组。ELISA法测定血清APN水平。结果对照组、左心室正常构型组、左心室向心性重构组之间血清APN水平比较差异无显著性(P〉0.05)。与对照组比较,左心室向心性肥厚组和左心室离心性肥厚组高血压病患者的血清APN水平显著降低(P〈0.01),日左心室离心性肥厚组APN水平下降的更明显(P〈0.01)。左心室肥厚组患者的血清APN水平与左心室质量指数呈显著的负相关(P〈0.05)。结论在规范化治疗的高血压病患者,血清APN水平仍能很好的反映左心室肥厚的程度。 Objective To investigate the relationship between serum adiponeetin ( APN ) level and left venlricular geomelry in patients with essential hypertension, blethods Echoeardiography was performed on 133 patients with essential hypertension. According to left ventricular mass index( LVMI ) and relative wall thickness ( RWT ), patients were divided into normal geometry group ( n = 37 ), concentric remodeling group( n=32 ), concentric hypertrophy group ( n = 34 )and eccentric hypertrophy group( n = 30 ). 30 healthy subjects were used as control. Serum APN levels were measured by enzymelinked immunosorbent assay. Results Serum APN levels did not differ significantly among the control group, the normal geometry group, and the concentric remodeling group ( P〉 0.05 ). As compared with those in the control group, serum APN levels were markedly lower in the concentric hypertrophy group and the eccentric hypertrophy group ( P〈 0.01 ), especially in the latter group ( P〈 0.01 ). APN levels were negatively related with LVMI ( P 〈 0.05 ) in those with ventricular hypertrophy. Conclusions Serum APN levels can still reflect the degree of left ventricular hypertrophy in hypertensive patients receiving standard therapies.
出处 《国际医药卫生导报》 2011年第11期1299-1302,共4页 International Medicine and Health Guidance News
关键词 高血压病 脂联素 左心室肥厚 Essential hypertension Adiponectin Left ventricular hypertrophy
  • 相关文献

参考文献12

  • 1Mangge H,Aimer G,Truschnig-Wilders M,et al.Inflammation,adiponectin,obesity and cardiovascular risk[J].Curr Med Chem,2010,17(36):4511-4520.
  • 2Mitsuhashi H,Yatsuya H,Tamakoshi K,et al.Adiponectin level and left ventricular hypertrophy in Japanese men[J].Hypertension,2007,49(6):1448-1454.
  • 3Mancia G,De Backer G,Dominiczak A,et al.2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension:ESH-ESC Task Force on the Management of Arterial Hypertension[J].J Hypertens,2007,25 (9):1751-1762.
  • 4Devereux RB,Alonso DR,Lutas EM,et al.Echocardiagraphic assessment of left ventricular hypertrophy:comparison to necropsy findings[J].Am J Cardiol,1986,57(6):450-458.
  • 5Ding G,Qin Q,He N,et al.Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma[J].J Mol Cell Cardiol,2007,43 (1):73-84.
  • 6Okamoto Y.Adiponectin provides cardiovascular protection in metabolic syndrome[J].Cardiol Res Pract,2011,23:313179.
  • 7Komaba H,Igaki N,Goto S,et al.Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus[J].Nephron Clin Pract,2007,107(3):c103-108.
  • 8Chow WS,Cheung BM,Tso AW,et al.Hypoadi-ponectinemia as a predictor for the development of hypertension:a 5-year prospective study[J].Hypertension,2007,49(6):1455-1461.
  • 9P(a)(a)kk(o)T,Ukkola O,Ik(a)eimo M,et al.Plasma adiponectin levels are associated with left ventricular hypertrophy in a random sample of middle-aged subjects[J].Ann Med,2010,42(2):131-137.
  • 10Konishi M,Haraguchi G,Ohigashi H,et al.Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation[J].Cardiovasc Res,2011,89(2):309-319.

同被引文献29

  • 1Winkler G, Cseh K. Molecular mechanisms and correlations of insulin resistance, obesity, and type 2 diabetes mellitus[J].Orv Hetil, 2009, 150 (17) : 771-780.
  • 2Miner JL. The adipocyte as endocrine cell[J]. J Anim Sci, 2004, 82 ( 4 ) : 935-940.
  • 3Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin ( nampt ) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes[J]. Exp Clin Endocrinol Diabetes, 2010, 118 (2) : 75-80.
  • 4Wan Y, Evans RM. Rosiglitazone activation of PPARgamma suppresses fractalkine signaling[J]. J Mol Endocrinol, 2010, 44 (2) : 135-142.
  • 5De Pauw A, Tejerina S, Raes M, et al. Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations[J]. Am J Pathol, 2009, 175 ( 3 ) : 927-939.
  • 6Kempf T, Eden M, Strelau J, et al. The transforming growth factor-13 superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury [J]. Cir Res, 2006, 98(10): 351-360.
  • 7Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation [J]. Cir Res, 2006, 98(3):342-350.
  • 8Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH- ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension [J]. J Hypertens, 2007, 25(9):1751-1762.
  • 9Mancia G, Laurent S, Agabiti-Rosei E, et al; European Society of Hypertension. Reappraisal of European guidelines on hypertension management [J]. J Hypertens, 2009, 27 (11):2121-2158.
  • 10Devereux RB, Alonso DR, Lutas EM, et al. Echocardiagraphic assessment of left ventricular hypertrophy: comparison to necropsy findings [J]. Am J Cardiol, 1986, 57(6):450-458.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部